文献速递骨肿瘤

骨盆原发骨肉瘤静脉瘤栓的临床与影像学研究

Venous Tumor Thrombus in Primary Bone Sarcomas in the Pelvis: A Clinical and Radiographic Study of 451 Cases.
PubMed 文献 · J Bone Joint Surg Am · 2021-01-01

本研究纳入451例连续的原发骨盆骨肉瘤患者,发现静脉瘤栓(VTT)总体患病率为9.8%,在骨盆骨肉瘤中高达22.6%。VTT与乳酸脱氢酶(LDH)水平升高及特定孔道侵犯相关,且VTT患者预后较差,中位总生存期仅14个月。

要点

  • 骨盆原发骨肉瘤VTT患病率9.8%,骨肉瘤亚组达22.6%。
  • VTT相关因素包括LDH≥230.5 U/L及侵犯L5-S1椎间孔。
  • VTT患者中位总生存期14个月,预后不良。

核心结论

  • VTT在骨盆骨肉瘤中最常见,且为不良预后因素。

研究设计与样本

  • 回顾性纳入451例连续的原发、骨源性、未经治疗的骨盆肉瘤病例,分析人口学、实验室、影像及肿瘤学评估资料。

主要发现

  • 队列包括软骨肉瘤41.2%、骨肉瘤30.4%、尤文肉瘤15.5%、骨源性未分化多形性肉瘤5.8%及其他骨肉瘤7.1%。
  • 骨盆骨肉瘤患者VTT患病率22.6%,相关因素包括软骨母细胞亚型、LDH≥187 U/L及侵犯闭孔和L5-S1椎间孔。
  • VTT患者中位总生存期14个月。
  • 局限期骨盆骨肉瘤亚组分析显示,VTT患者中位总生存期21.5个月 vs 无VTT者54.0个月(p=0.003),中位无复发生存期18.6 vs 32.4个月(p=0.020),中位无转移生存期11.2 vs 41.0个月(p<0.001)。

关键数值与推荐

  • VTT总体患病率9.8%,骨肉瘤亚组22.6%。
  • 相关因素:LDH≥230.5 U/L、侵犯L5-S1椎间孔;骨肉瘤亚组:软骨母细胞亚型、LDH≥187 U/L、侵犯闭孔和L5-S1椎间孔。
  • VTT患者中位总生存期14个月。

临床怎么用

  • 对骨盆骨肉瘤患者应警惕VTT,尤其存在LDH升高或L5-S1椎间孔侵犯时。
  • VTT分层管理算法可能有益,但需进一步验证。

局限性

  • 证据等级为预后Level IV。
  • VTT管理算法需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Few investigations of venous tumor thrombus (VTT) in primary pelvic bone sarcomas are available. We aimed to identify the prevalence, associated factors, and prognosis of VTT across different types of pelvic sarcomas and to propose an algorithm for management. METHODS: We included 451 consecutive cases of primary, bone-derived, treatment-naive, pelvic sarcomas in this study. Demographic data and the results of initial laboratory tests, imaging examinations, and oncological evaluations were extracted and analyzed. Forty-four cases of VTT were diagnosed with radiographic examinations, and 18 of them were verified histologically. RESULTS: The cohort consisted of chondrosarcomas (41.2%), osteosarcomas (30.4%), Ewing sarcomas (15.5%), bone-derived undifferentiated pleomorphic sarcomas (5.8%), and other bone sarcomas (7.1%). The prevalence of VTT was 9.8% in the whole group, and associated factors included a lactate dehydrogenase (LDH) level of ≥230.5 U/L and invasion of the L5-S1 intervertebral foramen. Patients with pelvic osteosarcoma had a high prevalence of VTT (22.6%), and the associated factors in this group included a chondroblastic subtype, an LDH level of ≥187 U/L, and invasion of the obturator foramen and the L5-S1 intervertebral foramen. Patients with VTT had a poor prognosis with a median overall survival time of 14 months. Subgroup analyses of localized pelvic osteosarcoma indicated that the presence of VTT decreased the median overall survival time (21.5 versus 54.0 months for those without VTT, p = 0.003), median recurrence-free survival time (18.6 versus 32.4 months, p = 0.020), and median metastasis-free survival time (11.2 versus 41.0 months, p < 0.001). CONCLUSIONS: VTT is most common in patients with pelvic osteosarcoma as compared with patients with other primary bone sarcomas, and it is associated with several factors. It is a negative prognostic factor. An algorithm for management of pelvic sarcomas with VTT stratified by the classification of the VTT might be beneficial, but further validation is necessary. LEVEL OF EVIDENCE: Prognostic Level IV. See Instructions for Authors for a complete description of levels of evidence.

来源:J Bone Joint Surg Am,查看原文。版权归原作者所有。

引用

  1. Liang H, Guo W, Tang X, et al. Venous Tumor Thrombus in Primary Bone Sarcomas in the Pelvis: A Clinical and Radiographic Study of 451 Cases. J Bone Joint Surg Am. 2021. PMID: 33857031. doi:10.2106/JBJS.20.00569

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。